This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions

Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions



Time to Complete

1 hour


April 13, 2018


April 13, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Sponsored by the Academy for Continued Healthcare Learning

Commercial Supporter

This activity is supported by an educational grant from Gilead Sciences, Inc.

Program Description

Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are chronic, systemic, autoimmune disorders characterized by inflammatory processes. There are numerous classes of therapies available to treat RA and IBD, and some patients achieve low disease activity or remission, yet a proportion of patients exhibits an inadequate response and/or discontinues therapy due to tolerability. As such, investigations into new targets and therapies, such as the janus kinase (JAK) inhibitors, continue. The introduction of JAK inhibitors further contributes to a growing armamentarium of therapies for these immune-mediated inflammatory diseases. Evolving strategies for employing the JAK inhibitors present a decision-making challenge to clinicians who treat these patients.

Bring this content to your institution! To educate your staff and earn additional CME credit, please contact Michelle Forcier at 773-714-0705 x118.

Intended Audience

This activity is intended for gastroenterologists, rheumatologists and other clinicians interested in learning more about the JAK/STAT signaling pathway.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of immune-mediated inflammatory diseases
  • Evaluate the use of JAK inhibitors in immune-mediated inflammatory diseases such as RA and IBD
  • Interpret clinical trial efficacy and safety data of JAK inhibitors under investigation across inflammatory diseases
  • Outline approaches to educating patients on the role of JAK inhibition, including efficacy and safety data

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.


Russell Cohen, MD (Moderator)
Professor of Medicine
Directory, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
University of Chicago Medical Center
Chicago, IL

Dr. Cohen discloses the following:
Speakers’ Bureau: AbbVie, Takeda Pharmaceuticals, Inc.
Consultant/Advisory Board: AbbVie, Celgene Corporation, Entera Health, Inc., Hospira, Janssen, Pfizer, Inc., Sandoz Biopharmaceuticals, Takeda Pharmaceuticals, Inc., UCB S.A.
Clinical Investigator: AstraZeneca, Celgene Corporation, Gilead Sciences, Inc., MedImmune, Mesoblast Ltd., Osiris Therapeutics, Inc., Pfizer Inc., Receptos, RedHill Biopharma, Sanofi-Aventis, USB S.A.

William Rigby, MD (Faculty)
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Dr. Rigby discloses the following:
Consulting Agreements: Bristol-Myers Squibb, Pfizer Inc., Roche

Joel Pekow, MD (Faculty)
Assistant Professor of Medicine
Section of Gastroenterology, Hepatology and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL

Dr. Pekow discloses the following:
Sources of Funding for Research: AbbVie, Takeda Pharmaceuticals, Inc.
Consultant/Advisory Board: Janssen, Pfizer, Inc., Verastem Inc.

Accredited Provider Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: JAK inhibitors under investigation for RA and IBD.


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


To obtain credit, a score of 75% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Inquiries may be directed to ACHL at (877) 444-8435 x228.


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue